Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 315-329 , September 2009

Interferon in chronic myeloid leukaemia: past and future

References 

  1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212–214
  2. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–554
  3. Smit WM, Rijnbeek M, van Bergen CA, et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukaemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 1998;95:10152–10157
  4. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310–2318
  5. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood. 1990;76:2462–2465
  6. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  7. Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. Virology. 1984;132:211–216
  8. Merlin G, Falcoff E, Aguet M. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J Gen Virol. 1985;66:1149–1152
  9. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489–2499
  10. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994;91:1198–1205
  11. Harada H, Taniguchi T, Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie. 1998;80:641–650
  12. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835–1837
  13. Nagamura-Inoue T, Tamura T, Ozato K. Transcription factors that regulate growth and differentiation of myeloid cells. Int Rev Immunol. 2001;20:83–105
  14. Nelson N, Kanno Y, Hong C, et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol. 1996;156:3711–3720
  15. Driggers PH, Ennist DL, Gleason SL, et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1990;87:3743–3747
  16. Weisz A, Marx P, Sharf R, et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem. 1992;267:25589–25596
  17. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukaemias. Blood. 1998;91:22–29
  18. Schmidt M, Hochhaus A, Nitsche A, et al. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukaemia correlates with pretreatment risk features and cytogenetic response to interferon-{alpha}. Blood. 2001;97:3648–3650
  19. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukaemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000;20:1149–1161
  20. Tamura T, Kong HJ, Tunyaplin C, et al. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood. 2003;102:4547–4554
  21. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukaemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307–317
  22. Deng M, Daley GQ. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood. 2001;97:3491–3497
  23. Asselin-Paturel C, Boonstra A, Dalod M, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol. 2001;2:1144–1150
  24. Schiavoni G, Mattei F, Sestili P, et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8 alpha(+) dendritic cells. J Exp Med. 2002;196:1415–1425
  25. Sacchi S, Kantarjian H, O'brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukaemia. J Clin Oncol. 1995;13:2401–2407
  26. Paquette RL, Hsu N, Said J, et al. Interferon-alpha induces dendritic cell differentiation of CML mononuclearcells in vitro and in vivo. Leukemia. 2002;16:1484–1489
  27. Oka T, Sastry KJ, Nehete P, et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998;12:155–163
  28. Holyoake T, Jiang X, Eaves C, et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukaemia. Blood. 1999;94:2056–2064
  29. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325
  30. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532–4539
  31. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926–935
  32. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–908
  33. Sato T, Onai N, Yoshihara H, et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009;15:696–700
  34. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237–249
  35. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998;95:15623–15628
  36. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89:957–964
  37. Peschel C, Aulitzky WE, Huber C. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment—impact on treatment of myeloproliferative disorders. Leuk Lymphoma. 1996;22(Suppl. 1):129–134
  38. Bhatia R, Verfaillie CM. The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk Lymphoma. 1998;28:241–254
  39. Dowding C, Gordon M, Guo AP, et al. Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma. 1993;11:185–191
  40. Talpaz M, Kantarjian H, McCredie KB, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987;69:1280–1288
  41. Kantarjian M, O'Brien S, Anderlini P, et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069–3081
  42. Niederle N, Kloke O, Wandl UB, et al. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma. 1993;9:111–119
  43. Ozer H, George S, Schiffer C, et al. Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood. 1993;82:2975–2984
  44. Alimena G, Morra E, Lazzarino , et al. Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood. 1989;72:642–647
  45. Freund M, Von Wussow P, Diedrich H, et al. Recombinant human interferon(IFN) alpha-2b in chronic myelogenous leukemia. Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989;72:350–356
  46. Schofield JR, Robinson WA, Murphy JR, et al. Low doses of Interferon-* are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994;121:736–744
  47. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood. 1994;84:4064–4077
  48. Allan N, Richards S, Shepherd P, et al. UK Medical Research Council randomized, multicentre trial of interferon-a n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392–1397
  49. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86:906–916
  50. Italian Cooperative Group on Chronic Myeloid Leukemia . Interferon-a-2b compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825
  51. Italian Cooperative Study Group on Chronic Myeloid Leukemia . Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541–1548
  52. The Benelux CML Study Group . Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-alpha2b for chronic myeloid leukemia. Blood. 1998;91:2713–2721
  53. Hehlmann R, Berger U, Pfirrmann M, et al. Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon a and hydroxyurea. Leukemia. 2003;17:1529–1537
  54. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616–1620
  55. Sokal JE, Gockerman JP, Bibner SH. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leukemia Res. 1988;12:453–458
  56. Guilhot F, Dreyfus B, Brizard A, et al. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha2a and hydroxyurea with or without low dose cytosine-arabinoside. Leuk Lymphoma. 1991;4:49–55
  57. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chrosomome-positive chronic myelogenous leukemia with Interferon-* and low-dose cytarabine. J Clin Oncol. 1992;10:772–778
  58. Kantarjian H, O'Brien S, Beran M, et al. Interferon alpha (IFN-A) and low-dose cytosine arabinoside (Ara-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood. 1995;86(Suppl. 1):abs n°2105
  59. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229
  60. Guilhot F, Guerci A, Maloisel F, et al. Follow-up of 1047 patients with chronic myelogenous leukemia treated with interferon or interferon with cytarabine. Blood. 1997;90(Suppl. 1):Abs 2299
  61. Baccarani M, Rosti G, De Vivo A, et al. A randomized study of interferon-* and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–1535
  62. Kühr T, Burgstaller S, Apfelbeck U, et al. A randomized study comparing interferon (IFNa) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res. 2003;27:405–411
  63. Maloisel F, Guerci A, Guyotat D, et al. Results of a phase II trial of a combination or oral cytarabine ocfosfate (YNK01) and interferon-*2b for treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. 2002;16:573–580
  64. Rosti G, Bonifazi F, Trabacchi E, et al. A phase II study of a-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia. 2003;17:554–559
  65. Cervantes F, Sureda A, Hernandez-Boluda JC, et al. Interferona plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. Haematologica. 2001;86:1281–1286
  66. Kühr T, Eisterer W, Apfelbeck U, et al. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study. Leuk Res. 2000;24:583–587
  67. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  68. Lucy JE, Jorgensen HG, Mountford JC, et al. Punish the parent not the progeny. Blood. 2005;105:1862–1866
  69. Lipton JH, Khoroshko ND, Golenkov AK, et al. Phase II, randomized, multicenter, comparative study of peginterferon alfa-2a(40 KD) versus interferon alfa -2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma. 2007;48:497–505
  70. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004;18:309–315
  71. Baccarani M, Martinelli G, Rosti G, et al. Imatinib an pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood. 2004;104:4245–4251
  72. Palandri F, Iacobucci I, Castagnetti F, et al. Front line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5 year outcome. Haematologica. 2008;93:770–774
  73. O'Brien S, Vallance SE, Craddock C, et al. PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloïd leukemia. Blood. 2001;98:3512a
  74. Hehlmann R, Sau S, Lauseker M, et al. Randomized clinical trial for the optimization of Imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV. Haematologica. 2009;94(Suppl. 2):0478
  75. Rousselot P, Preudhomme C, Guilhot J, et al. Molecular responses of the SPIRIT phase III trial of the French CML group comparing Imatinib 400 mg to higher dose Imatinib or combination with interferon or cytarabine for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients. Haematologica. 2009;94(Suppl. 2):1093
  76. Alimena G, Breccia M, Luciano L, et al. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. Leuk Res. 2008;32:255–261
  77. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-α a study complete cytogenetic responders. Blood. 2001;98:3074–3081
  78. Parmar S, Smith J, Sassano A, et al. Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood. 2005;106:7

PII: S1521-6926(09)00075-9

doi: 10.1016/j.beha.2009.10.005

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 315-329 , September 2009

Article Tools

* Image Usage & Resolution